Wellcome Trust Sanger Institute's Director Honoured: Allan Bradley Elected to Royal Society
Professor Allan Bradley, Director of the Wellcome Trust Sanger Institute, has been elected to Fellowship of the Royal Society, an honour regarded as the UK's premier scientific accolade. The Royal Society today (13 May 2002) announced the election of 42 new Fellows and 6 Foreign Members from the fields of science, engineering and technology.
Professor Bradley took over as Director of the Wellcome Trust Sanger Institute in 2000 to develop programmes to capitalize on decoding the human genome and other genomes. He is a world leader in the field of stem cell research - methods he and his colleagues developed in the early 1980s that today provide one of the most promising routes for understanding and treating genetic disease. Stem cells allow researchers to study in precise detail the role of individual genes and groups of genes.
"It is a great honour to be included among an impressive list of new fellows elected by the Royal Society this year. The Fellows of the Royal Society are all scientists who have made major contributions to their fields, and all young researchers aspire to be recognized among its membership. This recognition is important for the Wellcome Trust Sanger Institute, we have exciting times ahead as we move to postgenomic research, this recognition in part reflects the importance of our future work."
Professor Allan Bradley, Director of the Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute has played a key role in sequencing of the human genome and ensuring the results are freely available to all in the public domain. In October 2001, the Wellcome Trust announced new funding of £ 300M to support the Institute's plans to translate sequence information into biomedical benefit.
Under this plan, new areas of research will complement the existing skills in genomics to accelerate translation of genomic information into new biological knowledge and medical treatments. Professor Bradley's research is an integral part of the Sanger Institute's vision.
"I am delighted that this honour has been awarded to Professor Bradley. He has been instrumental in developing and exploiting stem cell technology to bring new understanding for biomedicine. His work at the Wellcome Trust Sanger Institute will bring real benefit from genome research, the overriding aim of the Human Genome Project."
Dr Mike Dexter, FRS, Director of the Wellcome Trust
"I'm very pleased that this has happened. It is a well-deserved tribute to 15 years' of Allan's work that has made possible the genetic manipulation of mice with all it entails for research in biology and medicine. You don't get elected to the Royal Society just for being worthy or for organising, but rather for your own science."
Sir John Sulston, FRS, former Director of the Wellcome Trust Sanger Institute
The Sanger Institute, funded largely by the Wellcome Trust, is completing one-third of the human genome, contributing to projects on the mouse and other animal genomes, as well as genomes of disease-causing organisms such as TB and malaria.